Europe - Euronext Paris - EPA:ALIKO - FR00140048X2 - Common Stock
The current stock price of ALIKO.PA is 1.615 EUR. In the past month the price increased by 9.86%. In the past year, price increased by 4.19%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.78 | 109.21B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 19.29 | 52.00B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 16.52 | 23.54B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 16.52 | 23.54B | ||
| BIM.PA | BIOMERIEUX | 29.74 | 13.59B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 147.87 | 4.45B | ||
| DIA.MI | DIASORIN SPA | 21.82 | 4.04B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 26.3 | 3.79B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 11.16 | 1.35B | ||
| ELN.MI | EL.EN. SPA | 22.44 | 1.15B | ||
| DRW8.DE | DRAEGERWERK AG | 8.99 | 1.09B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 24.18 | 998.53M |
Ikonisys SA specializes in the design, manufacture, and distribution of cellular diagnosis applications for cancer, genetic diseases, and fertility problems. The company is headquartered in Paris, Ile-De-France and currently employs 10 full-time employees. The company went IPO on 2021-07-19. The firm offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. The company utilizes advanced molecular and immunological markers, Ikoniscope robotic components, software engine, image acquisition, digital microscope and cell detection to design and deliver accurate and reliable detection of rare cells. The company includes clinical diagnostic applications for the diagnosis of different types of cancer, including bladder (oncoFISH bladder), breast (oncoFISH her2), cervical (oncoFISH cervical), prostate (oncoFISH PTEN), lung (oncoFISH ALK) and a variety of hematological cancers utilizing the Explorer applications.
IKONISYS SA
62 Rue De Caumartin, Paris 9
Paris ILE-DE-FRANCE FR
Employees: 10
Ikonisys SA specializes in the design, manufacture, and distribution of cellular diagnosis applications for cancer, genetic diseases, and fertility problems. The company is headquartered in Paris, Ile-De-France and currently employs 10 full-time employees. The company went IPO on 2021-07-19. The firm offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. The company utilizes advanced molecular and immunological markers, Ikoniscope robotic components, software engine, image acquisition, digital microscope and cell detection to design and deliver accurate and reliable detection of rare cells. The company includes clinical diagnostic applications for the diagnosis of different types of cancer, including bladder (oncoFISH bladder), breast (oncoFISH her2), cervical (oncoFISH cervical), prostate (oncoFISH PTEN), lung (oncoFISH ALK) and a variety of hematological cancers utilizing the Explorer applications.
The current stock price of ALIKO.PA is 1.615 EUR. The price decreased by -2.71% in the last trading session.
ALIKO.PA does not pay a dividend.
ALIKO.PA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
ALIKO.PA stock is listed on the Euronext Paris exchange.
IKONISYS SA (ALIKO.PA) currently has 10 employees.
ChartMill assigns a technical rating of 8 / 10 to ALIKO.PA. When comparing the yearly performance of all stocks, ALIKO.PA turns out to be only a medium performer in the overall market: it outperformed 50.36% of all stocks.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
9 analysts have analysed ALIKO.PA and the average price target is 2.86 EUR. This implies a price increase of 76.84% is expected in the next year compared to the current price of 1.615.